期刊文献+

法匹拉韦的合成 被引量:13

Synthesis of favipiravir
下载PDF
导出
摘要 目的设计并探索一条工艺稳定、收率较高的抗病毒化合物法匹拉韦(T-705)的合成工艺路线。方法以氨基丙二酸二乙酯盐酸盐为起始原料,氨水氨解后与乙二醛环合得到3-羟基-2-吡嗪酰胺、经硝酸钾硝化后制得3-羟基-6-硝基-2-吡嗪酰胺,再经三氯氧磷氯代、氟化钾氟代制得3,6-二氟-2-氰基吡嗪,水解成盐,最后经过氧化氢(双氧水)氧化制得目标化合物法匹拉韦。结果设计出的合成路线能有效制备目标化合物。结论该合成路线各步反应中除氟取代需要严格去水外,其余各步反应条件较温和且操作简单、收率稳定,适合规模制备。 Objective To design and investigate an effective synthetic route of the antivirus compound favipiravir (T-705) with a stable and high yield. Methods The commercial available diethyl aminomalonate hydrochloride was selected as the starting material The product of aminolysis was cyclized with glyoxal to yield 3-hydroxy-2-pyraziamide, which was subjected to nitration with KNO3, chlorination and dehydration with POC13 and fluorination with KF to afford 3, 6-difluoropyrazin-2-carbonnitrile. The difluorate product was further hydrolyzed and oxidized to give favipiravlr. Results The target compound was efficiently prepared by the above synthetic route. Conclusion The reaction conditions are mild except the fluoro-substitution, in which all reagents should be dried completely. The synthetic procedure is simple, high-yield and suitable for scale preparation.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2015年第2期220-224,共5页 Journal of International Pharmaceutical Research
关键词 抗病毒化合物 法匹拉韦 合成 antivirus compound favipiravir synthesis
  • 相关文献

参考文献15

  • 1Sangawa H, Komeo T, Nishikawa H, et ol. Mechanism of action T-705 ribosyl triphosphate against influenza virus RNA polymerase [ J ]. A ntimicrob Agents Chemother , 2013,57 ( 11 ): 5202-5208. 被引量:1
  • 2Furuta Y, Takahashi K, Shiraki K, et oi. T-705(favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections [ J ]. A ntiviral Res , 2009,82 : 95-102. 被引量:1
  • 3Furuta Y, Gowen B B, Takahashi K, et al. Favipiravir (T- 705), a novel viral RNA polymerase inhibitor [J]. Antiviral Res, 2013,100: 446-454. 被引量:1
  • 4Oestereich L, Liidtke A, Wurr S, et ol. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model [J]. Antiviral Res, 2014,105: 17-21. 被引量:1
  • 5Seharton D, Bailey K W, Bailey, et ol. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment [J]. Antiviral Res, 2014,104: 84-92. 被引量:1
  • 6Furuta Y. Nitrogenous heterocyclie carboxamide derivatives or salts t hereof and antiviral agents containing both: WO, 00/01569 FP~. 2003-03-02. 被引量:1
  • 7郑家晴,张涛,刘昌铭,等.6-氟-3-羟基-2-吡嗪酰胺的制备方法:CN102775358A[P].2012-11-14. 被引量:1
  • 8张涛,孔令金,李宗涛,袁洪雨,徐文方.法匹拉韦的合成[J].中国医药工业杂志,2013,44(9):841-843. 被引量:11
  • 9王欢,李行舟,钟武.法匹拉韦的合成[J].中国医药工业杂志,2014,45(11):1009-1012. 被引量:13
  • 10Fujlmoto T, Hashlmoto T, Hayashi K, et ol. Crystal of 5- hydroxy-lH-imidazole-4-carboxamide 3/4 hydrate, method for producing the same and crystal of 5-hydroxy-lH-imidazole-4- carboxamide hydrate: US, 2014/0275568A1 [P]. 2014-09-18. 被引量:1

二级参考文献22

  • 1Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound I"-705 [J]. Antimierob Agents Chemother, 2002, 46 (4): 977-981. 被引量:1
  • 2Kiso M, Takahashi K, Sakai-Tagawa Y, et al. To705 (favipiravir) activity against lethal H5N1 influenza A viruses [J]. Proc Natl Aead Sei U S A, 2010, 107 (2) : 882-887. 被引量:1
  • 3Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections [J]. Antimierob Agents Chemother, 2007, 51 (9) : 3168-3176. 被引量:1
  • 4Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 [J]. Antimicrob Agents Chemother, 2009, 53 (1): 202-209. 被引量:1
  • 5Furuta Y. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both: WO, 00/10569 [P]. 2003-03-02. 被引量:1
  • 6Forns P, Esteve C, Taboada L, et al. Pyrazine-based Syk kinase inhibitors [J]. Bioorg Med Chem. Lett, 2012, 22 (8) : 2784-2788. 被引量:1
  • 7Charrier JD, Durrant S J, Golec JM, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents [J]. JMed Chem, 2011, 54 (7) : 2320-2330. 被引量:1
  • 8Caldwell J J, Veillard N, Collins I. Design and synthesis of 2 (1H) -pyrazinones as inhibitors of protein kinases [J]. Tetrahedron, 2012, 68 (2012) : 9713-9728. 被引量:1
  • 9Beldar SV, Jordis U. Synthetic studies towards the antiviral pyrazine derivative T-705[C]//13th International Electronic Conference on Synthetic Organic Chemistry, 2009. 被引量:1
  • 10Tamio H. Method for producing dichloropyrazine derivative: WO, 2010/087117 [P]. 2012-08-05. 被引量:1

共引文献16

同被引文献42

引证文献13

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部